- Trials with a EudraCT protocol (6,492)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6,492 result(s) found for: Standard care.
Displaying page 86 of 325.
| EudraCT Number: 2022-002494-28 | Sponsor Protocol Number: 6 | Start Date*: 2023-05-18 | |||||||||||
| Sponsor Name:Consorcio Centro de Investigacion Biomedica en Red, (CIBER) | |||||||||||||
| Full Title: Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of intravenous metoprolol in patients with Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
| Medical condition: Intensive Care Unit patients with Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-001443-31 | Sponsor Protocol Number: RC12_0447 | Start Date*: 2013-12-30 |
| Sponsor Name:CHU de Nantes | ||
| Full Title: Phase II trial studying the efficacy of a triplet combination of MLN9708, lenalidomide and dexamethasone as induction prior to, and as consolidation after high-dose therapy with peripheral stem cel... | ||
| Medical condition: Young untreated patients with multiple myeloma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-003815-25 | Sponsor Protocol Number: CP0101-CLL | Start Date*: 2022-02-21 |
| Sponsor Name:CellPoint B.V. | ||
| Full Title: A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (C... | ||
| Medical condition: relapsed / refractory Chronic Lymphocytic Leukemia relapsed / refractory Small Lymphocytic Lymphoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-003296-18 | Sponsor Protocol Number: LDX0119 | Start Date*: 2020-12-30 | ||||||||||||||||
| Sponsor Name:DOMPé FARMACEUTICI S.P.A. | ||||||||||||||||||
| Full Title: Effect of oral ladarixin 400 mg twice a day on insulin sensitivity. A phase 2, randomized, double-blind, placebo-controlled explorative study in obese patients with pre-diabetes eligible to bariatr... | ||||||||||||||||||
| Medical condition: Obesity and pre-diabetes | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2018-003617-17 | Sponsor Protocol Number: NCT03348735 | Start Date*: 2018-12-03 |
| Sponsor Name:Antwerp University Hospital (UZA) | ||
| Full Title: Efficacy, patient acceptability and safety of topical treatment versus systemic treatment: a randomized, multicenter, comparative pragmatic trial in adult patients suffering from diverse localized ... | ||
| Medical condition: Patients suffering from localized neuropathic pain (LNP) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-003787-24 | Sponsor Protocol Number: PM-CARE-PNRR-MAD-2022-12375905 | Start Date*: 2023-04-20 | ||||||||||||||||
| Sponsor Name:OSPEDALE SAN RAFFAELE | ||||||||||||||||||
| Full Title: Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (Single arm, multicenter phase II study investigating the efficacy and safety... | ||||||||||||||||||
| Medical condition: Unresectable intrahepatic cholangiocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2022-003070-23 | Sponsor Protocol Number: CLITRETVER | Start Date*: 2023-01-27 | |||||||||||
| Sponsor Name:Verisfield S.M.S.A. | |||||||||||||
| Full Title: A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence for the comparison of clindamycin + tretinoin/Verisfield gel (1+0.025)% with Acn... | |||||||||||||
| Medical condition: Acne Vulgaris | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-003282-98 | Sponsor Protocol Number: OLT1177-07 | Start Date*: 2018-03-07 | |||||||||||
| Sponsor Name:Olatec Therapeutics LLC | |||||||||||||
| Full Title: A Pilot, Open-Label, Phase 2, Single-Center, Repeat Dose, Proof-of-Concept Safety, Pharmacodynamics and Efficacy Study of Orally Administered Dapansutrile Capsules in Subjects with Schnitzler’s Syn... | |||||||||||||
| Medical condition: Schnitzler's syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-003415-29 | Sponsor Protocol Number: 2.0 | Start Date*: 2023-04-03 | |||||||||||
| Sponsor Name:Leiden University Medical Centre | |||||||||||||
| Full Title: The effect of antenatal acetaminophen administration on breathing effort of premature infants at birth: a pilot study | |||||||||||||
| Medical condition: Pregnant women expected to deliver between 24 and 30 weeks' gestation | |||||||||||||
|
|||||||||||||
| Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-006914-62 | Sponsor Protocol Number: BAY 43-9006 / 13266 | Start Date*: 2009-04-23 | |||||||||||||||||||||
| Sponsor Name:Bayer HealthCare AG, 51368 Leverkusen, Germany | |||||||||||||||||||||||
| Full Title: A Phase III, multi-center, placebo–controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2... | |||||||||||||||||||||||
| Medical condition: Non-small cell lung carcinoma in patients with predominantly non-squamous cell carcinoma histology | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Completed) BE (Completed) DE (Completed) AT (Completed) SE (Completed) ES (Completed) FR (Completed) BG (Completed) HU (Completed) GR (Completed) IT (Completed) GB (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2019-004183-21 | Sponsor Protocol Number: IP-001-18 | Start Date*: 2022-08-19 | |||||||||||
| Sponsor Name:Iperboreal Pharma Srl | |||||||||||||
| Full Title: A Study to Evaluate the EffIcacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis | |||||||||||||
| Medical condition: End-Stage Renal Disease (ESRD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-004936-36 | Sponsor Protocol Number: CLL13 | Start Date*: 2016-11-08 | |||||||||||
| Sponsor Name:University of Cologne | |||||||||||||
| Full Title: A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) ve... | |||||||||||||
| Medical condition: fit patients with previously untreated CLL without del(17p) or TP53 mutation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) DK (Completed) DE (Completed) AT (Completed) FI (Completed) BE (Completed) IE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003799-22 | Sponsor Protocol Number: CVT-301-005 | Start Date*: 2015-02-11 | |||||||||||
| Sponsor Name:Civitas Therapeutics, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Obser... | |||||||||||||
| Medical condition: Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) GB (Completed) CZ (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-005906-32 | Sponsor Protocol Number: WAKE-UP | Start Date*: 2012-09-24 | |||||||||||
| Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
| Full Title: Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial | |||||||||||||
| Medical condition: Patients with acute ischemic stroke proven by MRI and unknown time from symptom onset which otherwise fulfil the approval criteria for intravenous thrombolysis in acute stroke | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Completed) DK (Completed) ES (Completed) NL (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003721-22 | Sponsor Protocol Number: A4091058 | Start Date*: 2016-01-14 | ||||||||||||||||
| Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | ||||||||||||||||||
| Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP ... | ||||||||||||||||||
| Medical condition: Osteoarthritis of the hip or knee | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BG (Completed) SK (Completed) LT (Completed) HR (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-005053-25 | Sponsor Protocol Number: TRAM | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
| Sponsor Name:Institute of Mother and Child | ||||||||||||||||||||||||||||
| Full Title: Optimalization Of The Time And Dosage Of Trametinib In BRAF Negative Juvenile Patients With Refractory Histiocytosis Or After Failure Of Vemurafenib Treatment. | ||||||||||||||||||||||||||||
| Medical condition: histiocytic cell proliferation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-000874-92 | Sponsor Protocol Number: LUM-201-01 | Start Date*: 2021-03-22 | |||||||||||
| Sponsor Name:Lumos Pharma, Inc. | |||||||||||||
| Full Title: A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficie... | |||||||||||||
| Medical condition: Growth hormone deficiency | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-000104-15 | Sponsor Protocol Number: CCS1477-02 | Start Date*: 2021-07-29 |
| Sponsor Name:CellCentric Ltd | ||
| Full Title: An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies. | ||
| Medical condition: Acute Myeloid Leukaemia (AML)/high-risk Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Non-Hodgkin Lymphoma(NHL). | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-005120-16 | Sponsor Protocol Number: 62638 | Start Date*: 2018-11-02 | |||||||||||
| Sponsor Name:Amsterdam UMC, Location VUmc | |||||||||||||
| Full Title: Ulipristal versus standard surgical treatment in symptomatic uterine fibroids | |||||||||||||
| Medical condition: Uterine fibroids are very common during reproductive years in women. Minimally invasive treatments are emerging. Myomectomy is the gold standard, preferably laparoscpically, because it removes the ... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-004052-11 | Sponsor Protocol Number: UC-HNG/1909 | Start Date*: 2020-07-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, previously untreated, with indication of primary surgery. Patients with a di... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.